News
Nov 16, 2020
Ribon Therapeutics to Present at the Piper Sandler 32nd Annual Virtual Healthcare Conference
Cambridge, MA – November 16, 2020 – Ribon Therapeutics, a clinical stage oncology company developing first-in-class therapeutics targeting stress response pathways, today announced that Victoria …
Learn MoreNov 09, 2020
Ribon Therapeutics Announces the Appointment of Emma Reeve to the Company’s Board of Directors
Cambridge, MA – November 9, 2020 – Ribon Therapeutics, a clinical-stage oncology company developing first-in-class therapeutics targeting stress response pathways, today announced the appointment of …
Learn MoreJul 16, 2020
Ribon Therapeutics Announces Appointment of Jodie P. Morrison as Chair of the Company’s Board of Directors
Cambridge, MA – July 16, 2020 – Ribon Therapeutics, a clinical-stage oncology company developing first-in-class therapeutics targeting stress response pathways, today announced that Jodie P. …
Learn MoreJun 22, 2020
Ribon Therapeutics Presents Additional Preclinical Data on its PARP7 Inhibitor – RBN-2397 – and Demonstrates Broad Potential of its Platform at the AACR 2020 Virtual Meeting II
-Reinforces PARP7 as a novel therapeutic target and that inhibition of PARP7 induces both antitumor immunity and cancer cell-intrinsic effects– -Platform identifies several cancer-relevant monoPARPs …
Learn MoreMay 26, 2020
Ribon Therapeutics to Present at the Jefferies Virtual Healthcare Conference
Cambridge, MA – May 26, 2020 – Ribon Therapeutics, a clinical stage oncology company developing first-in-class therapeutics targeting stress response pathways, today announced that Victoria …
Learn MoreMay 15, 2020
Ribon Therapeutics to Present New Preclinical Data on its PARP7 Inhibitor – RBN-2397 – and its Discovery Platform at the Upcoming AACR 2020 Virtual Meeting II
-RBN-2397 restores type I IFN signaling in the tumor, causes complete tumor regressions and adaptive immunity in preclinical models- Cambridge, MA – May 15, 2020 …
Learn MoreMay 04, 2020
Ribon Therapeutics to Present at Upcoming Healthcare Conferences
Cambridge, MA – May 4, 2020 — Ribon Therapeutics, a clinical-stage oncology company developing first-in-class therapeutics targeting stress response pathways, today announced that Victoria Richon, …
Learn MoreApr 27, 2020
Ribon Therapeutics Presents Preclinical Data from its PARP7 and PARP14 Programs at AACR Virtual Meeting I
— Lead program, PARP7 inhibitor RBN-2397, demonstrates complete tumor regression in preclinical cancer models — — Phase 1 study underway evaluating RBN-2397 in advanced-stage solid …
Learn MoreApr 14, 2020
Ribon Therapeutics to Present New Preclinical Data at the Upcoming AACR Virtual Annual Meetings
Cambridge, MA – April 14, 2020 – Ribon Therapeutics, a clinical stage oncology company developing first-in-class therapeutics targeting stress response pathways, today announced the presentation …
Learn MoreJan 24, 2020
Ribon Therapeutics to Present at Upcoming Scientific Conferences
Cambridge, MA – Jan. 24, 2020 – Ribon Therapeutics, a clinical stage biotechnology company developing first-in-class therapeutics targeting novel enzyme families activated under cellular stress …
Learn MoreJan 06, 2020
Ribon Therapeutics Named as a Top Life Sciences Company to Watch in 2020
BioSpace is proud to present its NextGen Bio “Class of 2020,” a list of up-and-coming life sciences companies in North America…
Learn MoreDec 18, 2019
Ribon Therapeutics Strengthens Scientific Advisory Board with Appointment of Neal Rosen, M.D., Ph.D.
Cambridge, MA – Dec. 18, 2019 – Ribon Therapeutics, a clinical stage biotechnology company developing first-in-class therapeutics targeting novel enzyme families activated under cellular stress …
Learn MoreSep 04, 2019
Ribon Therapeutics Announces Dosing of First Patient in Phase 1 Clinical Trial of RBN-2397, a First-In-Class PARP7 Inhibitor
PARP7 is a Novel Tumor Dependency, Enabling Cancer Cells to Evade the Immune System First Ever Clinical Evaluation of a monoPARP Inhibitor Cambridge, MA – …
Learn MoreAug 06, 2019
Ribon Therapeutics Strengthens Management Team with Appointment of Sudha Parasuraman, M.D., as Chief Medical Officer and Edward Stewart as Chief Business Officer
Cambridge, MA – Aug. 6, 2019 – Ribon Therapeutics, a clinical stage biotechnology company, developing first-in-class therapeutics targeting novel enzyme families activated under cellular stress …
Learn MoreJan 04, 2019
Ribon Therapeutics Raises $65 Million to Advance Pipeline of Novel Therapeutics Targeting Cellular Stress Pathways for Cancer
Financing led by the Novartis Venture Fund, with Johnson & Johnson Innovation – JJDC, Inc. (JJDC), Celgene, and existing investors, The Column Group, Deerfield Management, …
Learn More